RESEARCH PAPER

Artificial Intelligence and Machine Learning Applications in Drug Delivery Technology: A Review

Dr. Namrata Bhatt[1], Dr. Upendra Singh[2]

[1]Assistant Professor, Dept. of Information Security and Cloud Computing, Sviit, Shri Vaishnav Vidyapeeth Vishwavidyalaya, Indore, Mp, India

Email: n.03633sharma@gmail.com

[2]Assistant Professor, Department of Information Technology, Shri G.S. Institute of Technology and Science, Indore, India

Email: upendrasingh49@gmail.com, usingh@sgsits.ac.in

Received: 17th Mar, 2026 | Revised: 29th Mar, 2026 | Accepted: 19th Apr, 2026 | Available Online: 5th May, 2026

ABSTRACT

Artificial Intelligence (AI) and Machine Learning (ML) have emerged as transformative technologies in pharmaceutical sciences and drug delivery systems. The integration of AI-based computational approaches with advanced drug delivery technologies has significantly improved formulation design, predictive modeling, targeted therapy, pharmacokinetic and pharmacodynamic analysis, and personalized medicine. This review highlights the recent applications of AI and ML in drug delivery technology, including nanocarrier optimization, smart drug delivery systems, transdermal delivery, controlled drug release, and AI-assisted pharmaceutical manufacturing. Various AI techniques such as deep learning, artificial neural networks, predictive analytics, and machine learning algorithms are extensively utilized for improving drug release prediction, bioavailability, stability, toxicity assessment, and formulation optimization. AI-driven systems also contribute to reduced development costs, enhanced therapeutic efficacy, and minimization of experimental trials. The review discusses the role of AI in personalized medicine, adaptive drug delivery, real-time monitoring, and intelligent therapeutic systems. Despite substantial advancements, several challenges remain, including limited standardized datasets, ethical concerns, regulatory barriers, data privacy issues, and insufficient clinical validation. AI and ML demonstrate enormous potential in revolutionizing drug delivery technology and advancing patient-centric healthcare systems through intelligent and adaptive therapeutic approaches.

Keywords: Artificial Intelligence, Machine Learning, Drug Delivery Systems, Nanotechnology, Personalized Medicine

How to cite this article: Bhatt N, Singh U., Artificial Intelligence and Machine Learning Applications in Drug Delivery Technology: A Review. Int J Drug Deliv Technol. 2026;16(43s): 692-701; Doi: 10.25258/Ijddt.16.43s.71

1. Introduction

Drug delivery technology plays a crucial role in modern pharmaceutical sciences by improving the therapeutic efficacy, safety, and bioavailability of medicinal compounds. Conventional drug delivery approaches such as oral administration, injections, and topical therapies often suffer from several limitations including poor drug solubility, non-specific targeting, rapid drug degradation, low bioavailability, and adverse side effects. These challenges reduce treatment effectiveness and may negatively impact patient compliance. To overcome these limitations, advanced drug delivery systems such as controlled release formulations, targeted nanocarriers, transdermal patches, liposomes, polymeric nanoparticles, and smart therapeutic systems have been developed. These modern systems provide site-specific drug delivery, sustained release, and improved pharmacokinetic behavior, thereby enhancing therapeutic outcomes and minimizing toxicity [1].

In recent years, Artificial Intelligence (AI) and Machine Learning (ML) have emerged as revolutionary technologies in healthcare and pharmaceutical research. AI refers to the simulation of human intelligence using computational algorithms capable of performing learning, reasoning, prediction, and decision-making tasks. Machine Learning, a subset of AI, enables systems to automatically learn from large datasets and improve prediction accuracy without explicit programming [2]. The integration of AI and ML into pharmaceutical sciences has significantly transformed drug discovery, dosage form development, manufacturing, pharmacokinetic and pharmacodynamic modeling, toxicity prediction, and personalized medicine. AI-driven computational tools can analyze massive biological and pharmaceutical datasets, including genomics, proteomics, and clinical information, to identify disease targets, optimize formulations, and predict drug responses with higher accuracy and efficiency [3].

The application of AI in drug delivery technology has gained considerable attention due to its ability to optimize formulation parameters, predict drug release behavior, enhance bioavailability, and support targeted drug delivery systems. Machine learning algorithms such as Artificial Neural Networks (ANNs), Deep Learning (DL), Convolutional Neural Networks (CNNs), and Recurrent Neural Networks (RNNs) have shown excellent performance in pharmaceutical modeling and prediction tasks [4]. AI-assisted nanotechnology has further enabled the development of intelligent nanocarriers capable of adaptive drug release, biomarker sensing, and personalized therapeutic monitoring. Additionally, AI-based predictive analytics reduce the need for extensive trial-and-error experiments and minimize development costs and time.

The major motivation behind this review is the increasing need for intelligent and personalized drug delivery systems capable of addressing complex healthcare challenges. Despite substantial advancements in pharmaceutical technologies, several problems still exist, including variability in patient response, limited clinical translation, formulation instability, high research costs, regulatory barriers, and insufficient prediction accuracy using traditional methods [5]. AI and ML technologies provide promising solutions to these problems by enabling data-driven decision-making, predictive modeling, real-time monitoring, and adaptive therapeutic strategies. However, the implementation of AI in drug delivery systems still faces challenges related to data quality, model interpretability, ethical concerns, privacy issues, and lack of standardized regulatory frameworks. Therefore, a comprehensive understanding of current advancements, applications, limitations, and future opportunities is essential for researchers and healthcare professionals [6].

This review aims to systematically summarize recent developments in AI and ML applications in drug delivery technology. The key contributions of this review include: (i) comprehensive discussion of AI and ML techniques used in pharmaceutical sciences; (ii) analysis of AI-driven nanotechnology and smart drug delivery systems; (iii) evaluation of predictive modeling approaches in formulation optimization and pharmacokinetic studies; (iv) identification of current challenges, research gaps, and regulatory concerns; and (v) exploration of future directions for personalized and adaptive drug delivery systems.

The remainder of this paper is organized as follows: Section 2 presents the literature review related to AI and ML applications in drug delivery systems. Section 3 discusses the identified research gaps and limitations in current studies. Section 4 provides the conclusion of the review and summarizes the major findings. Section 5 highlights the future scope and emerging opportunities of AI-enabled drug delivery technologies in pharmaceutical sciences and personalized healthcare systems.

2. Literature Review

2. 1. Artificial Intelligence and Machine Learning in Drug Delivery Systems

Drug delivery systems have evolved significantly from conventional oral and parenteral administration methods toward advanced targeted and controlled delivery technologies. Traditional delivery systems often suffered from poor bioavailability, non-specific distribution, and severe side effects. Recent developments in nanotechnology, biomaterials, and computational sciences have improved therapeutic precision and patient compliance. Artificial Intelligence (AI) and Machine Learning (ML) have further transformed drug delivery systems by enabling predictive modeling, personalized medicine, and adaptive therapeutic strategies. AI-based systems can analyze pharmacokinetic and pharmacodynamic parameters to optimize dosing and reduce inter-individual variability in drug response

Researchers have highlighted that AI technologies provide rapid and intelligent solutions to pharmaceutical challenges by integrating genomics, proteomics, and biological databases for drug discovery and delivery optimization. Machine learning algorithms assist in experimental design, prediction of toxicity, optimization of lead compounds, and reduction in animal testing.

Furthermore, AI supports personalized medicine approaches through the analysis of patient-specific clinical data, thereby improving therapeutic outcomes and treatment adherence. These advancements indicate that AI has become a central component in pharmaceutical formulation design and dosage form optimization [2].

Several studies have emphasized that AI applications in pharmaceutical sciences extend beyond formulation development into manufacturing, quality control, supply chain optimization, and predictive maintenance. Serrano et al. explained that AI-driven pharmaceutical systems improve efficiency while reducing development costs and enhancing patient outcomes through predictive analytics and computational intelligence [3]. Similarly, Colombo discussed how AI contributes to the design, engineering, and manufacturing of nanoscale drug delivery systems through continuous optimization and reverse engineering approaches [4].

The growing importance of AI in drug development has also been associated with its ability to support virtual screening, target identification, and de novo drug design. AI methodologies such as deep learning, neural networks, and machine learning have enabled pharmaceutical researchers to accelerate drug development processes while minimizing failure rates. Studies reported that AI platforms can identify disease-associated targets and predict drug-target interactions with greater accuracy, thereby revolutionizing pharmaceutical technology and drug delivery sciences [5,7].



Figure 1. Artificial Intelligence and Machine Learning in Drug Delivery Systems

This figure 1 illustrates the evolution of drug delivery systems from conventional approaches to advanced AI and ML-assisted technologies. Conventional drug delivery methods are associated with limitations such as low bioavailability, non-specific distribution, and adverse side effects. Advanced drug delivery systems integrate controlled release mechanisms, nanoscale carriers, and targeted delivery approaches. The incorporation of Artificial Intelligence and Machine Learning enables predictive modeling, dose optimization, pharmacokinetic and pharmacodynamic modeling, and personalized medicine, ultimately improving therapeutic outcomes and treatment efficiency.

2. AI-Driven Nanotechnology and Smart Drug Delivery Systems

Nanotechnology-based drug delivery systems have gained substantial attention due to their enhanced targeting capability, improved stability, and reduced toxicity. Various nanocarriers including liposomes, dendrimers, solid lipid nanoparticles, polymeric nanoparticles, nanoemulsions, nanoshells, and carbon nanotubes have demonstrated remarkable therapeutic efficiency in drug delivery applications. The integration of AI with nanotechnology has significantly improved the characterization, optimization, and performance prediction of these nanocarriers [6].

AI models have been successfully used to predict critical quality attributes such as particle size, zeta potential, encapsulation efficiency, and drug release kinetics. These predictive capabilities reduce experimental burden and improve formulation precision. Zhu et al. reported that machine learning algorithms enhance drug solubility, stability, and bioavailability while optimizing novel drug delivery systems including nanocarriers and personalized drug release platforms [8]. AI also contributes to intelligent manufacturing technologies such as continuous manufacturing and 3D printing, which support the development of advanced pharmaceutical formulations.

Smart drug delivery systems represent another major advancement where AI enables responsive and adaptive therapeutic approaches. Panchpuri et al. described how AI-powered smart delivery systems can deliver drugs to specific tissues and cells while minimizing side effects. Techniques such as deep learning, genetic algorithms, and Internet of Things (IoT)-based healthcare platforms are increasingly being incorporated into drug delivery technologies. AI-integrated biosensors and theragnostic systems further support personalized medicine by combining diagnostics with targeted therapy [9].

The application of AI in targeted cancer therapy has also shown promising results. Nanoparticle-mediated drug delivery integrated with AI allows biomarker sensing, prediction of nanoparticle-drug interactions, and evaluation of drug efficacy. AI algorithms help classify cancer types and improve precision medicine approaches for cancer patients. Das reported that the convergence of nanoparticles and AI significantly enhances localized drug delivery and therapeutic effectiveness in oncology applications [11].



Figure 2. AI Driven Nanotechnology and Smart Drug Delivery Systems

This figure 2 demonstrates the integration of artificial intelligence with nanotechnology for the development of smart drug delivery systems. Different nanocarrier systems such as liposomes, dendrimers, polymeric nanoparticles, solid lipid nanoparticles, and nanoemulsions are represented. Machine learning techniques assist in predicting particle size, encapsulation efficiency, formulation stability, and release kinetics. Smart drug delivery functions including targeted delivery, adaptive drug release, real-time monitoring, and patient-specific therapy contribute toward precision drug delivery and personalized healthcare applications.

3. Machine Learning Algorithms and Predictive Modeling in Pharmaceutical Technology

Machine learning and artificial neural networks (ANNs) have become essential computational tools in pharmaceutical sciences. Various ANN models including multilayer perceptron networks (MLP), recurrent neural networks (RNNs), convolutional neural networks (CNNs), and radial basis function networks (RBFN) are widely used in drug formulation optimization and predictive modeling. These models can analyze complex biological datasets and establish relationships between formulation variables and therapeutic outcomes [10].

AI-driven predictive models have shown considerable success in pharmacokinetics, toxicity prediction, and drug release estimation. Studies demonstrated that machine learning algorithms accurately predict drug entrapment, release kinetics, skin permeation, and stability of transdermal drug delivery systems. Sabbagh et al. reported that ML models achieved approximately 93% prediction accuracy for drug entrapment in transdermal formulations, thereby streamlining pharmaceutical development processes and minimizing reliance on extensive clinical trials [15].

Artificial neural networks have also been applied in controlled drug delivery systems to estimate release profiles of therapeutic agents. Rafienia et al. utilized feed-forward neural networks including MLP, GRNN, and RBFN models to predict the release profiles of betamethasone and betamethasone acetate from in situ forming systems. Their findings indicated that MLP models outperformed other neural network approaches in reliability and efficiency for controlled release predictions [21].

AI has further contributed to dosage optimization and pharmacokinetic/pharmacodynamic (PK/PD) modeling. Computational intelligence techniques facilitate the prediction of bioactive compounds, toxicity profiles, in vitro–in vivo correlations (IVIVC), and structure-activity relationships. These applications significantly improve formulation development and reduce development time and cost. Researchers have highlighted that AI-based predictive modeling supports personalized dosage design and adaptive therapeutic interventions [16,18].



Figure 3. Machine Learning Algorithms and Predictive Modeling in Pharmaceutical Technology

This figure 3 explains the role of machine learning algorithms and predictive modeling in pharmaceutical formulation development and drug delivery optimization. Pharmaceutical and biological datasets are processed through machine learning techniques including artificial neural networks, deep learning, convolutional neural networks, and recurrent neural networks. These models are utilized for predicting drug release profiles, toxicity, permeation, bioavailability, and pharmacokinetic-pharmacodynamic behavior. The predictive outputs support formulation optimization by reducing experimental trials, improving prediction accuracy, lowering development costs, and enhancing overall drug performance.

4. Challenges, Future Perspectives, and Clinical Translation of AI in Drug Delivery

Despite significant advancements, several challenges continue to hinder the large-scale implementation of AI in pharmaceutical drug delivery systems. One major limitation is the availability of high-quality and standardized datasets required for training robust AI models. Small and heterogeneous datasets often reduce prediction reliability and limit clinical translation. Panjipour et al. emphasized that external validation, benchmarking, uncertainty quantification, and model interpretability remain critical requirements for trustworthy AI-enabled drug delivery systems [20].
Regulatory and ethical concerns also present major barriers to AI adoption in pharmaceutical sciences. The integration of AI into drug development processes requires clear regulatory frameworks to ensure safety, transparency, and reproducibility. Researchers have pointed out that issues related to patient data privacy, algorithm bias, and ethical use of AI technologies must be carefully addressed before widespread clinical implementation can occur [3,16].
Another challenge involves the complexity of integrating AI with emerging technologies such as stimuli-responsive materials, smart biosensors, and continuous manufacturing systems. Although AI-integrated transdermal patches, microneedles, and smart contact lenses demonstrate promising results, the practical scalability and commercialization of these technologies require further research and interdisciplinary collaboration [15,20].
Future perspectives indicate that AI will continue to revolutionize pharmaceutical sciences through personalized medicine, intelligent nanocarriers, real-time therapeutic monitoring, and adaptive drug delivery systems. Advances in deep learning, big data analytics, IoT integration, and AI-driven biosensors are expected to improve therapeutic precision and patient-centric healthcare. Continuous investment in AI research and pharmaceutical innovation is anticipated to enhance drug development efficiency, optimize treatment outcomes, and shape the future of next-generation drug delivery technologies [1,8,17].



Figure 4. Challenges and Future Perspectives of AI in Drug Delivery

This figure 4 highlights the major challenges, emerging technologies, and future perspectives associated with AI-enabled drug delivery systems. Current challenges include limited quality datasets, privacy concerns, regulatory barriers, low model interpretability, and the need for clinical validation. Emerging technologies such as smart biosensors, three-dimensional printing, responsive materials, and intelligent nanocarriers are shaping the next generation of pharmaceutical systems. Future directions focus on personalized medicine, real-time monitoring, adaptive drug delivery, and patient-centric healthcare, emphasizing the transformative potential of AI in modern pharmaceutical sciences.

Table 1: Systematic Review of Artificial Intelligence and Machine Learning in Drug Delivery Systems

Ref. No.	**Author and Year**	**Study Focus**	**AI or ML Technique Used**	**Drug Delivery Application**	**Key Findings**	**Limitations**
[1]	Asediya et al., 2025	AI and ML in drug delivery optimization	Machine Learning, Predictive Modeling	Personalized drug delivery	Improved PK/PD modeling and dose optimization	Need for real-time clinical validation
[2]	Vora et al., 2023	AI in pharmaceutical technology	AI algorithms, ML models	Dosage form design and testing	Reduced development cost and optimized formulation	Data dependency and regulatory concerns

[3]	Serrano et al., 2024	AI in personalized medicine	Machine Learning, Deep Learning	Drug discovery and delivery	Enhanced efficiency and patient outcomes	Ethical and regulatory challenges
[4]	Colombo, 2020	AI in pharmaceutical development	AI-based computational methods	Nanosystem manufacturing	Continuous optimization of nanosystems	Limited industrial translation
[5]	Visan and Negut, 2024	AI assisted drug discovery	Deep Learning and ML	Drug delivery design	Accelerated target identification and screening	High computational requirements
[6]	Alshawwa et al., 2022	Nanocarrier drug delivery systems	AI integrated nanotechnology	Nanocarrier optimization	Enhanced stability and targeting efficiency	Manufacturing and safety limitations
[7]	Agrawal et al., 2024	AI in pharmaceutical drug delivery	Artificial Intelligence models	Drug delivery optimization	Reduced research and development cost	Limited practical implementation
[8]	Zhu et al., 2025	AI driven pharmaceutical development	Machine Learning	DDS optimization and ADMET prediction	Improved bioavailability and drug release control	Data quality concerns
[9]	Panchpuri et al., 2025	Smart drug delivery systems	ML, Deep Learning, Genetic Algorithms	Personalized medicine	Adaptive drug release and IoT integration	Technical complexity
[10]	Vijaya et al., 2023	AI applications in DDS	Artificial Neural Networks	Drug targeting and formulation	Improved IVIVC and QSAR modeling	Requirement of large datasets
[11]	Das, 2023	AI and nanoparticles in cancer therapy	AI algorithms	Targeted cancer drug delivery	Better biomarker sensing and targeting	Limited clinical studies
[12]	Shukla and Singh, 2025	AI in drug development	ML and AI techniques	Drug development and delivery	Reduced animal testing and improved	Ethical concerns

					prediction	
[13]	Vora et al., 2023	AI in dosage form design	AI and ML models	Pharmaceutical dosage forms	Enhanced patient adherence and PK prediction	Need for regulatory frameworks
[14]	Pravalika and Sandeep, 2023	AI in pharmaceutical sciences	ANN, DNN, RNN	Drug discovery and formulation	Improved QSPR and QSAR analysis	Early stage technological adoption
[15]	Sabbagh et al., 2025	AI in transdermal DDS	Machine Learning, Predictive Analytics	Transdermal patches and microneedles	93% prediction accuracy in drug entrapment	Data privacy and scalability issues
[16]	Aundhia et al., 2025	AI impact on drug delivery	AI driven sensors and predictive systems	Smart drug carriers	Personalized and adaptive therapy	Biocompatibility concerns
[17]	Deori et al., 2024	AI role in novel DDS	AI algorithms and ML	Nanoparticles and liposomes	Improved efficacy and reduced side	Regulatory limitations
					effects	
[18]	Mutha et al., 2024	AI overview in pharmaceuticals	ML, Deep Learning, NLP	Drug delivery and dose optimization	Enhanced PK/PD and clinical trial design	Dependence on computational resources
[19]	Asediya et al., 2025	AI and ML in DDS optimization	Predictive AI models	Adaptive therapeutic systems	Personalized and responsive therapy	Clinical implementation barriers
[20]	Panjipour et al., 2026	AI in corneal drug delivery	ML models and inverse design	Ocular drug delivery	Improved permeability and release prediction	Small and heterogeneous datasets
[21]	Rafienia et al., 2010	ANN in controlled DDS	MLP, RBFN, GRNN	Controlled drug release	MLP showed superior prediction performance	Limited formulation variables studied

Table 1 presents a systematic review of recent studies related to the application of Artificial Intelligence (AI) and Machine Learning (ML) in drug delivery systems and pharmaceutical sciences. The reviewed studies demonstrate that AI-based technologies, including machine learning, deep learning, artificial neural networks, predictive analytics, and computational modeling, have significantly contributed to the optimization of drug delivery systems, personalized medicine, dosage form design, pharmacokinetic and pharmacodynamic modeling, nanocarrier development, and targeted drug delivery. Several researchers reported improvements in drug release prediction, bioavailability, therapeutic efficacy, formulation optimization, and reduction in research and development costs through AI-assisted approaches. The studies also highlight the growing role of AI in smart drug delivery systems, transdermal patches, cancer-targeted therapy, ocular delivery systems, and adaptive therapeutic platforms. Despite these advancements, multiple limitations were identified, including lack of standardized datasets, regulatory and ethical concerns, data privacy issues, high computational requirements, limited clinical validation, scalability challenges, and industrial implementation barriers. Overall, the systematic review indicates that AI and ML possess strong potential to revolutionize pharmaceutical drug delivery systems; however, further research, clinical translation, and regulatory development are essential for their widespread practical application.

3. Research Gap

Despite the rapid advancement of Artificial Intelligence (AI) and Machine Learning (ML) in pharmaceutical sciences and drug delivery systems, several critical research gaps still exist. Most of the currently available studies primarily focus on theoretical models, computational predictions, and laboratory-scale experiments, while limited research has been translated into real-time clinical applications. The absence of large-scale clinical validation studies restricts the practical implementation of AI-enabled drug delivery systems in routine healthcare settings. Another major gap is the limited availability of high-quality, standardized, and diverse pharmaceutical datasets required for training robust AI and ML models. Many existing models are developed using small and heterogeneous datasets, which reduce prediction reliability, reproducibility, and generalizability. Furthermore, external validation and benchmarking of AI models against conventional pharmaceutical approaches remain insufficient, creating challenges in model accuracy and trustworthiness.

Although AI-integrated nanocarriers, smart biosensors, transdermal systems, and personalized drug delivery platforms have demonstrated promising outcomes, there is still inadequate understanding regarding their long-term safety, toxicity, biocompatibility, and regulatory compliance. Current studies mainly emphasize formulation optimization and prediction tasks, whereas limited attention has been given to the scalability, industrial manufacturing feasibility, and commercialization of AI-based drug delivery technologies. In addition, interpretability and transparency of AI algorithms continue to be important concerns in pharmaceutical research. Most deep learning and neural network models function as "black box" systems, making it difficult for researchers and regulatory authorities to understand the exact reasoning behind predictions and decisions. Ethical concerns related to patient data privacy, cybersecurity, and bias in AI-driven healthcare systems also require further investigation. Moreover, integration of emerging technologies such as Internet of Things (IoT), wearable biosensors, smart nanomaterials, continuous manufacturing, and three-dimensional printing with AI-based drug delivery systems is still at an early stage. There is a lack of interdisciplinary frameworks capable of combining these technologies into unified, adaptive, and patient-centric therapeutic platforms. Therefore, future research should focus on developing clinically validated, interpretable, secure, and scalable AI-driven drug delivery systems supported by standardized datasets and strong regulatory frameworks. Greater emphasis is needed on personalized medicine, real-time therapeutic monitoring, adaptive drug release systems, and translational research to bridge the gap between laboratory innovation and clinical implementation.

4. Conclusion

Artificial Intelligence (AI) and Machine Learning (ML) have emerged as transformative technologies in pharmaceutical sciences and drug delivery systems. The integration of AI with advanced drug delivery technologies has significantly improved formulation design, predictive modeling, pharmacokinetic and pharmacodynamic analysis, targeted drug delivery, and personalized medicine. AI-driven computational approaches enable rapid analysis of complex biological and pharmaceutical datasets, reducing development time, cost, and experimental burden while enhancing therapeutic efficacy and patient compliance. The application of AI in nanotechnology-based drug delivery systems, smart biosensors, transdermal delivery platforms, and intelligent nanocarriers has further accelerated the development of precision medicine. Machine learning algorithms such as artificial neural networks, deep learning, convolutional neural networks, and recurrent neural networks have demonstrated excellent capabilities in predicting drug release kinetics, toxicity, bioavailability, and formulation stability. Moreover, AI-assisted systems provide opportunities for adaptive drug release and real-time therapeutic monitoring, thereby supporting patient-centric healthcare approaches.

Despite these advancements, several challenges remain, including limited availability of high-quality datasets, lack of standardized validation protocols, regulatory barriers, ethical concerns, and limited clinical translation. Many AI models still require improved transparency, interpretability, and external validation before their widespread implementation in pharmaceutical industries and healthcare systems. Overall, AI and ML possess enormous potential to revolutionize modern drug delivery systems by enabling intelligent, adaptive, and personalized therapeutic strategies. Continued interdisciplinary collaboration among pharmaceutical scientists, data scientists, biomedical engineers, and regulatory agencies will be essential for translating AI-driven innovations from research laboratories into real-world clinical applications.

5. Future Scope

1. **Development of Personalized Drug Delivery Systems :** Future research should focus on AI-powered personalized medicine approaches capable of designing patient-specific dosage regimens based on genetic, physiological, and clinical data. Adaptive drug delivery systems integrated with biosensors and real-time monitoring technologies can further improve therapeutic precision and treatment outcomes.
2. **Integration of AI with Emerging Technologies :** The combination of AI with nanotechnology, Internet of Things (IoT), wearable biosensors, smart nanomaterials, continuous manufacturing, and three-dimensional printing offers promising opportunities for the development of next-generation intelligent drug delivery platforms. These technologies may enable automated and stimuli-responsive drug release systems.
3. **Clinical Translation and Regulatory Framework Development :** Greater emphasis should be placed on large-scale clinical trials, validation studies, and development of standardized regulatory guidelines for AI-enabled pharmaceutical systems. Future efforts should also address data privacy, cybersecurity, ethical considerations, and algorithm transparency to improve clinical acceptance and industrial implementation.
4. **Advanced Predictive Modeling and Real-Time Monitoring ;** Future AI models are expected to provide highly accurate predictions for pharmacokinetics, toxicity, bioavailability, and therapeutic responses. Real-time AI-assisted monitoring systems may support dynamic dose adjustments and continuous optimization of drug therapy, thereby improving patient safety, reducing adverse effects, and enhancing healthcare efficiency.

References

1. Asediya, V., Anjaria, P., Dhial, K., & Pathak, A. (2025). Artificial Intelligence and Machine Learning in Drug Delivery Optimization. In *Next-Generation Drug Delivery Systems* (pp. 499-521). New York, NY: Springer US.
2. Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023). Artificial intelligence in pharmaceutical technology and drug delivery design. *Pharmaceutics*, *15*(7), 1916.
3. Serrano, D. R., Luciano, F. C., Anaya, B. J., Ongoren, B., Kara, A., Molina, G., ... & Lalatsa, A. (2024). Artificial intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine. *Pharmaceutics*, *16*(10), 1328.
4. Colombo, S. (2020). Applications of artificial intelligence in drug delivery and pharmaceutical development. In *Artificial intelligence in healthcare* (pp. 85-116). Academic Press.
5. Visan, A. I., & Negut, I. (2024). Integrating artificial intelligence for drug discovery in the context of revolutionizing drug delivery. *Life*, *14*(2), 233.
6. Alshawwa, S. Z., Kassem, A. A., Farid, R. M., Mostafa, S. K., & Labib, G. S. (2022).

Nanocarrier drug delivery systems: characterization, limitations, future perspectives and implementation of artificial intelligence. *Pharmaceutics*, *14*(4), 883.

7. Agrawal, G., Tushir, S., Arora, D., & Sangwan, K. (2024, May). Artificial intelligence in pharmaceutical drug delivery. In *2024 international conference on computational intelligence and computing applications (ICCICA)* (Vol. 1, pp. 406-410). IEEE.
8. Zhu, T., Liu, B., Chen, N., Liu, Y., Wang, Z., & Tian, X. (2025). Artificial intelligence-driven innovations in pharmaceutical development and drug delivery systems. *Current topics in medicinal chemistry*, *25*(25), 2937-2951.
9. Panchpuri, M., Painuli, R., & Kumar, C. (2025). Artificial intelligence in smart drug delivery systems: A step toward personalized medicine. *RSC pharmaceutics*, *2*(5), 882-914.
10. Vijaya, R., Lincy, B. C., RamanG, G., Kirubakaran, N., Chacko, L., Bhupathyraaj, M., ... & Alharbi, H. F. (2023). Applications of Artificial Intelligence in Drug Delivery Systems. In *Artificial intelligence in Pharmaceutical Sciences* (pp. 42-53). CRC Press.
11. Das, K. P. (2023). Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges. *Frontiers in medical technology*, *4*, 1067144.
12. Shukla, G., & Singh, D. (2025). Artificial intelligence: an innovative tool for the drug development and drug delivery system. *Biomedical Materials & Devices*, 1-12.
13. Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. (2023). *Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics. 2023; 15: 1916*.
14. Pravalika, T., & Sandeep, K. (2023). Artificial intelligence in pharmaceutical technology and drug delivery design. *World Journal of Pharmaceutical Research*, *12*(18), 391.
15. Sabbagh, F., Zakrzewska, A., Rybak, D., Król, J., Abdi, A., Nakielski, P., & Pierini, F. (2025). Transdermal Drug Delivery Systems Powered by Artificial Intelligence. *Advanced Healthcare Materials*, *14*(32), e03030.
16. Aundhia, C., Parmar, G., Talele, C., Shah, N., & Talele, D. (2025). Impact of artificial intelligence on drug development and delivery. *Current Topics in Medicinal Chemistry*, *25*(10), 1165-1184.
17. Deori, C., Hujuri, L., Sarma, G., & Sonowal, T. (2024). Artificial Intelligence (AI): It's Role in Drug Discovery and Novel Drug Delivery System. *Int J Sci Res*, *13*(2), 1426-30.
18. Mutha, R. E., Bagul, V. S., Tade, R. S., & Vinchurkar, K. (2024). An overview of artificial intelligence (AI) in drug delivery and development. *AI Innovations in Drug Delivery and Pharmaceutical Sciences; Advancing Therapy through Technology*, 1-27.
19. Asediya, V., Anjaria, P., Dhial, K., & Pathak, A. (2025). Artificial Intelligence and Machine Learning in Drug Delivery Optimization. In *Next-Generation Drug Delivery Systems* (pp. 499-521). New York, NY: Springer US.
20. Panjipour, A., Sojdeh, S., Arabpour, Z., & Djalilian, A. R. (2026). Artificial Intelligence in Corneal Drug Delivery Systems. *BioMedInformatics*, *6*(2), 11.
21. Rafienia, M., Amiri, M., Janmaleki, M., & Sadeghian, A. (2010). Application of artificial neural networks in controlled drug delivery systems. *Applied Artificial Intelligence*, *24*(8), 807-820.